Cellectar Biosciences (NASDAQ:CLRB) vs. The Competition Financial Contrast

Cellectar Biosciences (NASDAQ: CLRB) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Cellectar Biosciences to related companies based on the strength of its institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Risk & Volatility

Cellectar Biosciences has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Cellectar Biosciences’ competitors have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cellectar Biosciences and its competitors revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Cellectar Biosciences N/A -$10.78 million -1.23
Cellectar Biosciences Competitors $8.20 billion $2.68 billion -0.88

Cellectar Biosciences’ competitors have higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

2.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Cellectar Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -97.36% -83.40%
Cellectar Biosciences Competitors -2,859.75% -67.91% -9.23%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cellectar Biosciences and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences 0 0 2 0 3.00
Cellectar Biosciences Competitors 836 3751 6775 185 2.55

Cellectar Biosciences currently has a consensus price target of $2.70, indicating a potential upside of 76.47%. As a group, “Pharmaceuticals” companies have a potential upside of 27.88%. Given Cellectar Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectar Biosciences is more favorable than its competitors.


Cellectar Biosciences competitors beat Cellectar Biosciences on 7 of the 12 factors compared.

About Cellectar Biosciences

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply